A victory for the petitioners in King v. Burwell will not return the healthcare insurance marketplace to the pre-Affordable Care Act status quo.
Healthcare spending grew faster than the rest of the economy last year despite the ongoing reduction in hospital use and an industrywide campaign to hold down costs. How can that be?
Forget the smiley face the administration will put on the final numbers from the Affordable Care Act open-enrollment season that just ended. Sign-ups are lagging far behind original projections. And with the political and legal landscape littered with landmines, it's not going to get any easier.
Despite the extraordinary gains in public health brought about by vaccinations, there has never been a shortage of people who balk at the scientifically proven method for preventing infectious disease.
The dictionary defines vaporware as a product that has been widely advertised but has not and may never become available. Last week's twin announcements on the imminent move to widespread value-based reimbursement in healthcare bring the concept to mind.
Nearly two decades ago, Harvard Business School professor Clayton Christensen coined the phrase “disruptive innovation” to describe new technologies that transform industries by bringing simplicity and affordability to products and processes that are complicated and high cost.
Telehealth, which has been around for four decades, lives in regulatory limbo, despite being one of the more promising technologies for improving patient outcomes and lowering costs.
The Food and Drug Administration's proposal to regulate the accuracy of laboratory-developed tests has drawn heated opposition from the laboratory testing industry, hospitals and most medical specialty societies. Only oncologists favor tighter oversight.
Sorting through the shards of Vermont's discarded single-payer health insurance scheme reveals the plan was undone by its generosity toward patients, hospitals and physicians, not its core assumptions.
The holiday season is a time when we count our blessings and shower gifts on those we love. It's also the time when we vow to do better in the coming year.
Before the mass resignations at The New Republic, one of the new executives hired by its 31-year-old sugar-daddy owner reportedly asked for a "listicle" on “10 reasons why healthcare isn't a free market.” He didn't get it, but what a great idea.
That's the updated estimate of the cost to develop a new drug from the Tufts Center for the Study of Drug Development. Anyone with even a rudimentary understanding of corporate accounting knows the claim is bogus.